Delaying diagnostic procedure significantly increases mortality in patients with invasive mucormycosis-Reference-Cited by-同舟云学术

Delaying diagnostic procedure significantly increases mortality in patients with invasive mucormycosis

Published:2015-11-13 Issue:12 Volume:58 Page:746-752
ISSN:0933-7407
Container-title:Mycoses
language:en
Short-container-title:Mycoses

Author:

Jeong Su Jin¹,Lee Ji Un¹,Song Young Goo¹,Lee Kyoung Hwa¹,Lee Min Joo¹

Affiliation:

1. Division of Infectious Diseases; Department of Internal Medicine; Gangnam Severance Hospital; Yonsei University College of Medicine; Seoul Republic of Korea

Publisher

Wiley

Subject

Infectious Diseases,Dermatology,General Medicine

Reference31 articles.

1. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis;Chamilos;Clin Infect Dis,2008

2. Epidemiology and treatment of mucormycosis;Lewis;Future Microbiol,2013

3. Novel perspectives on mucormycosis: pathophysiology, presentation, and management;Spellberg;Clin Microbiol Rev,2005

4. Iron acquisition: a novel perspective on mucormycosis pathogenesis and treatment;Ibrahim;Curr Opin Infect Dis,2008

5. Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3);Skiada;Haematologica,2013

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Invasive fungal rhinosinusitis: current evidence and research opportunities;Current Opinion in Otolaryngology & Head & Neck Surgery;2024-07-19

2. Clinical features of pediatric mucormycosis: role of metagenomic next generation sequencing in diagnosis;Frontiers in Cellular and Infection Microbiology;2024-06-10

3. Mucormycosis after CD19 chimeric antigen receptor T-cell therapy: results of a US Food and Drug Administration adverse events reporting system analysis and a review of the literature;The Lancet Infectious Diseases;2024-04

4. Baseline findings of a multicentric ambispective cohort study (2021–2022) among hospitalised mucormycosis patients in India;Mycology;2024-01-02

5. Pharmacoeconomic evaluation of isavuconazole, posaconazole, and voriconazole for the treatment of invasive mold diseases in hematological patients: initial therapy prior to pathogen differential diagnosis in China;Frontiers in Public Health;2023-12-19